
    
      This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV
      confirmatory study.The study is conducted in Chinese subjects aged 4 years and older with
      Niemann Pick Type C disease (NPC). Approximately 19 subjects will be enrolled in this study.
      The study will be conducted at 2 sites in China. Patients will be treated with miglustat for
      12 months, efficacy and safety outcomes will be measured
    
  